Nektar Starts Major Push In Opioid-Induced Constipation Space
Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters
You may also be interested in...
As Nektar reinvents itself, the specialty drug developer gets multi-million dollar validation from AstraZeneca in deal for NKTR-118.
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth
The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior